Aurobindo Pharma’s Dazublys, a trastuzumab biosimilar for HER2-positive cancers, gains EU approval, enhancing access to ...

Recurrence means that cancer has come back after initial treatment and a period during which it could not be detected. Even ...

CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

A mum from Banbury with breast cancer said a life-extending drug would be 'worth it', as a charity speaks out on the 'unfair' ...

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the “unfair” way they are assessed for use on the health service, a charity has warned. Breast Cancer Now ...

Jessie comically celebrated the fact that she’s been able to successfully go to the bathroom, writing, "I have now done a ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine ...